Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVax in Relapsed Ovarian Cancer
NCT00660101Phase 2Unknown
- Sponsor
- AVAX Technologies, Inc.
- Start
- Jun 2008
- Primary completion
- Dec 2015
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dinitrophenyl-modified ovarian cancer vaccine in ovarian cancer, sponsored by AVAX Technologies, Inc.. Status: unknown.
02
Drugs
autologous dinitrophenyl-modified ovarian cancer vaccine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00660101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660101.